Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2026)
30 slides from Sonoma Pharmaceuticals's investor presentation, January 2026
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation
Sonoma Pharmaceuticals, Inc. Investor Presentation January 2026
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of
Slide 3: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma’s
Slide 4: Investment Highlights
Investment Highlights Over 20 years of experience developing and manufacturing products containing HOCl, over 100 research articles, papers and clinical and case studies, active U.S. and international patents, and continual product innovation Hypochlorous Acid Industry 22 U.S. FDA clearances as 510(
Slide 5: Sonoma's Microcyn Technology
Sonoma’s Microcyn® Technology Patented, Stabilized Triple-Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • Relieves pain and itch • Improves wound care by cleaning and moistening the wound and peri-wound area • Safely manage skin abrasio
Slide 6: Sonoma's Microcyn Technology
Sonoma’s Microcyn® Technology Unparalleled Safety • No drug-to-drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all-natural hypochlorous acid Indust
Slide 7: Over 100 research articles and case and clinical studies
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn® technology • Dermodacyn® Disinfecting solution study on viability of SARS-CoV-2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn® study on cellular toxi
Slide 8: Wide Range of Applications
Wide Range of Applications Wound Care Dermatology Eye Care Animal Health Care Surface Disinfectants Podiatry Senior Care 8
Slide 9: Our Wound Care Business is Growing in the U.S. and Internationally
Our Wound Care Business is Growing in the U.S. and Internationally • Celebrating over 20 years of selling wound care • In August 2024, we added Medline Industries, LP as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States •
Slide 10: Industry-Leading Safe and Effective Dermatology Products
Industry-Leading Safe and Effective Dermatology Products • Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care • Line of office dispense products targeting growing med spa market • National Eczema Association Seal of Acceptance • National Psoriasis Foundation
Slide 11: Expanded Eye Care Product Line
Expanded Eye Care Product Line • Sonoma has the strongest FDA indications for eye care in the HOCl industry • OTC and prescription eye care sold into multiples channels • Strong MDR-compliant CE Mark for blepharitis in the EU • Animal health eye care sold in major chains including PetSmart and Tract
Slide 12: Robust U.S. and International Distribution Network
Robust U.S. and International Distribution Network OVER 40 GLOBAL PARTNERS AND GROWING We continue to: • Expand our presence in new markets by replicating what works in existing markets • Add new distribution partners and grow existing relationships • Co-develop innovative new products with partners
Slide 13: Cutting Edge Manufacturing
CUTTING EDGE MANUFACTURING • 57,153 square foot state-of-the-art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Global shipping into over 55 countries, with multiple methods for shipments • Highly traine
Slide 14: Manufacturing Facility
Manufacturing Facility
Slide 15: Growth Strategy
Growth Strategy Manufacturing capabilities can support significant future growth, leading to improved margins overall Continue to introduce new high margin products • Efficient, flexible and FDA-regulated manufacturing facility currently operating at only 40% capacity • Launch new applications of So
Slide 16: New Market Opportunities
New Market Opportunities Sonoma is expanding its partnerships and product offerings in the eye care, all-natural skin care, medical spa and animal health care industries. • The global eye care market size was estimated at USD $70.78 billion in 2023 and is projected to grow at a compound annual growt
Slide 17: Recent Business Developments
Recent Business Developments Introduction of new products using our Microcyn® technology • In August 2025 we announced the launch of our HOCl-based diaper rash product for infants and children into and other large retailers in the United States. • In December 2024, we announced the relaunch of our p
Slide 18: Recent Business Developments
Recent Business Developments Expanding commercialization opportunities by investing in R&D • We successfully transitioned all of our commercialized products in Europe, including eye care, wound care, scar gel, acne products and atopic dermatitis products to the new European Union (EU) Medical Device
Slide 19: Recent Business Developments
Recent Business Developments Continuously expanding our distributor network • In January 2025, we partnered with WellSpring Pharmaceutical Corporation for the sale of our Microcyn technology-based products to large retailers in the United States. • In March, June and July 2025, we expanded our agree
Slide 20: Key Financial Metrics
Key Financial Metrics Fiscal year ended March 31, 2025 - Revenues increased 12% compared to FY 2024 Net loss improved 29% compared to FY 2024 EBITDA loss improved 17% compared to FY 2024 Three and six months ended September 30, 2025 – Revenues increased 57% for the quarter and 38% for the si
Slide 21: APPENDIX: Product Portfolio
APPENDIX: Product Portfolio
Slide 22: Diverse Product Portfolio
Diverse Product Portfolio United States Podiacyn Lumacyn Microcyn Rx Acuicyn Nanocyn Reliefacyn Regenacyn Skin & Wound Care Eyelid & Eyelash Everyday Foot Care Clarifying Mist Hospital Grade Itch, Burn, Rash & Pain Care Scar Gel Hygiene Disinfectant Ocucyn Levicyn Celacyn Pediacyn Microcyn OTC Laser
Slide 23: U.S. Dermatology
U.S. Dermatology • Office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 23
Slide 24: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin and lacerations. • Sold in national pet-store retail chains a
Slide 25: EU Products
EU Products Solutions that work naturally for everybody Microdacyn60® Wound Care Ocudox® Epicyn® Gramaderm® Pediacyn® Eye lid solution Dermatology Dermatology Dermatology Keloid or Blepharitis Acne Atopic treatment hypertrophic treatment Dermatitis scar MicrocynAH® Animal Health Care 25
Slide 26: Direct-to-consumer products available through Shopify and Amazon EU
Direct-to-consumer products available through Shopify and Amazon EU U.S. Products EU Products 26
Slide 27: Middle East
Middle East Microdacyn, Microsafe Wound Care Face Cool, Anti-Microbial, Baby Cool, Foot Cool, Lady Cool GE vy Microsafe Disinfectant & Sanitizer
Slide 28: Asia
Asia Singapore, Malaysia, Thailand, China Indonesia Microcyn Hong Kong Wound Care South Korea BioDerm Biodacyn60 The Philippines MicrocynAH® Wound Care Microdacyn 28
Slide 29: Latin America Australia & New Zealand
Latin America Australia & New Zealand Gramacyn Epicyn Kit for Acne Skin Treat Scars Right from the Start 29
Slide 30: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 United States of America Phone: 1-(800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2026) on 6ix